New drug duo aims to wipe out cancer cells in returning blood cancers
NCT ID NCT05168930
Summary
This study is testing whether combining two targeted drugs, zanubrutinib and venetoclax, can effectively treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned after prior therapy. The goal is to see if this combination can achieve deep remissions by making cancer cells undetectable in the blood and bone marrow. The trial will enroll up to 45 participants who will receive treatment for about 15 months, with options for re-treatment if the cancer comes back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL LYMPHOCYTIC LYMPHOMA (SLL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact
-
New England Cancer Specialists
RECRUITINGScarborough, Maine, 04074, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
South Shore Hospital
RECRUITINGSouth Weymouth, Massachusetts, 02190, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.